Name of product: HumuLIN 70/30 KwikPen
Indication: HUMULIN 70/30 is an insulin indicated to improve glycemic control in adult
patients with diabetes mellitus.
Ingredient(s): 70% insulin isophane (NPH insulin, intermediate-acting) and 30% insulin regular
(short-acting)
Contraindications
Hypersensitivity to insulin or any of the excipients
Episodes of hypoglycemia (due to the risk of severe hypoglycemia)
Interactions:
Drug-drug: meglitinides and sulfonylureas (increased risk of hypoglycemia), beta-blockers
(may mask the symptoms of hypoglycemia), ACE inhibitors (can potentiate hypoglycemia)
Drug-food: alcohol (increased risk of hypoglycemia, GI side effects), meals high in
carbohydrates are essential for managing insulin dosing.
Drug-lab test interactions: No specific insulin-related lab test interference, but frequent
glucose monitoring is required.
Dose/frequency/route:
o T1DM: not generally recommended in T1DM, initial TDD: subq 0.4-0.5 units/kg/day in
divided dose
o T2DM: Start with 0.2 -0.3 units/kg/day or 10-12 units/day in 2 or 3 divided doses
before meals (e.g. two-thirds of the dose before breakfast and one-third of the dose
before dinner)
Pharmacology: The combination of the two insulins provides both rapid onset for post-meal
glucose control and a prolonged effect to maintain basal glucose levels throughout the day.
Side effects: most common side effects are hypoglycemia, weight gain and injection site
reactions.
Goals of therapy: goal glucose target is individualized, for most DM patients are 80-180
mg/dL. HbA1c < 7%.
Action to take if overdose: Call 911, if patient is conscious and able to swallow, provide fruit
juice, glucose tablets, or administer glucagon.
Follow up with a healthcare provider regularly to adjust insulin doses based on blood sugar
control and any side effects experienced.
